About Panacea Diagnostics
Powering Diagnostics and Life Sciences for Health Preservation and Longevity
Who we are
Panacea’s mission is to help make health preservation trusted, affordable, accessible and sustainable for all.
Our vision is to empower researchers, healthcare professionals and consumers with personal precision healthcare and laboratory data from high quality and affordable tools and support the transition to prevention, prediction, participation and personalisation as the guardians of health and the key value drivers of the healthcare industry.
Our shared mission has brought the worlds of science and business together to create a single platform, adaptable to a wide range of challenges, from organoid analysis supporting drug development and precision medicine, through basic life sciences to rapid efficient clinical grade point of car, distributed diagnostics and health preservation.
Based in London, our board brings 60+ years of life sciences and diagnostics experience to bear on technology inspired and supported by our world-class Scientific Advisory Board.
Following years of quiet development, FreeFlow™ is now available to customers, partners and strategic collaborators across mutiple sectors.
If you need a platform for your innovative markers or just want to move standard laboratory tests to Point of Care, we have a solution. From single molecule sensitivity and high throughput to fully deskilled point of care with rapid readout.
Panacea Founding Partnership
Unique Technology, Deep Sector Expertise
Panacea’s leadership has 80+ years of experience in diagnostics and life sciences
David Klug
Professor of Chemical Biophysics
Associate Dean for Enterprise at Imperial College
Serial Entrepreneur
Finn Albrechtsen
SVP Global R&D and PMO at SSI Diagnostica Group
Former VP R&D and Business Development at Thermo Fisher Scientific Microbiology
17+ years of leadership experience in Diagnostics sector incl. Dako and Agilent Technologies
Michael Tillmann
Former CEO of Roche NA & APAC
Serial Diagnostics Entrepreneur
25 years of experience in senior executive and board positions
Giles Hamilton
Serial Diagnostics Entrepreneur
Developed technologies acquired by Baxter, Bio-Rad & J&J
25 years of experience in senior executive & board positions
Panacea's Scientific Advisory Board
From novel life sciences instrumentation to clinical use
Dr Vanya Gant
With over 15 years' experience in clinical diagnostics, Vanya was part of an EU team that created a highly successful "sample in/answer out" rapid molecular diagnostic platform. He was co-Principal Investigator in a 5 year NIHR programme grant investigating the performance and impact of several commercial rapid diagnostics platforms for deployment across UK ICUs.
Prof Sir David Klenerman
Dave Klenerman, along with Shankar Balasubramanian, invented a method of next-generation DNA sequencing which is commonly known today as the Solexa sequencing or Illumina dye sequencing and which is responsible for the vast majority of genetic sequencing across the globe. Their company Solexa was sold to Illumina for $600M in 2007
Prof Douglas Kell
Douglas is a systems biologist known for metabolic network modelling, the discovery of the bacterial resuscitation-promoting factor in organisms such as Mycobacterium tuberculosis, and the identification of amyloid blood clotting in chronic disease. He has served as CEO of the UK Biotechnology and Biological Sciences Research Council (BBSRC) and was later awarded a CBE for his scientific contributions, publishing over 500 papers with an H-index of 137.
